Scholarlink

<p>Experimental studies suggest that the probiotic yeast <i>Saccharomyces boulardii</i> can mitigate the symptoms of inflammatory bowel disease. However, these results are equivocal and <i>S. boulardii</i> probiotic therapy has not gained widespread acceptance in clinical practice. To assess whether the therapeutic properties of <i>S. boulardii</i> might be improved upon, we engineered <i>S. boulardii</i> to overproduce and secrete spermidine, a pro-regenerative natural metabolite. We employed CRISPR gene deletion and integration of gene cassettes at the <i>Ty2</i> locus to achieve high level polyamine synthesis and transport. We tested whether spermidine secreting <i>S. boulardii</i> could reduce disease symptoms in dextran sulfate sodium (DSS) and azoxymethane induced models of intestinal inflammation and cancer. We demonstrate that oral delivery of spermidine-secreting <i>S. boulardii</i> in mice populates the gastrointestinal tract with viable spermidine-secreting <i>S. boulardii</i> cells and raises free spermidine levels in the gastrointestinal tract. Strikingly, spermidine-secreting <i>S. boulardii</i> strains were significantly more effective than wild-type <i>S. boulardii</i> in reducing colitis symptoms as well as colitis-associated carcinogenesis in mice. These results suggest that in situ spermidine secretion by engineered synthetic biotic yeast strains may be an effective and low-cost therapy to mitigate inflammatory bowel disease and associated colon cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineered spermidine-secreting Saccharomyces boulardii ameliorates colitis and colon cancer in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月30日

查看全文
  • Mahdi Mohaqiq,
  • Roger Palou,
  • Ruizhen Li,
  • Guijun Zhang,
  • Het Vaishnav,
  • Florance Parweez,
  • Terence Moyana,
  • Damian Carragher,
  • D. W. Cameron,
  • Timothy Ramsay,
  • Almer M. van der Sloot,
  • Sanjay Murthy,
  • Brian K. Coombes,
  • Mike Tyers,
  • X. Johné Liu

摘要

Experimental studies suggest that the probiotic yeast Saccharomyces boulardii can mitigate the symptoms of inflammatory bowel disease. However, these results are equivocal and S. boulardii probiotic therapy has not gained widespread acceptance in clinical practice. To assess whether the therapeutic properties of S. boulardii might be improved upon, we engineered S. boulardii to overproduce and secrete spermidine, a pro-regenerative natural metabolite. We employed CRISPR gene deletion and integration of gene cassettes at the Ty2 locus to achieve high level polyamine synthesis and transport. We tested whether spermidine secreting S. boulardii could reduce disease symptoms in dextran sulfate sodium (DSS) and azoxymethane induced models of intestinal inflammation and cancer. We demonstrate that oral delivery of spermidine-secreting S. boulardii in mice populates the gastrointestinal tract with viable spermidine-secreting S. boulardii cells and raises free spermidine levels in the gastrointestinal tract. Strikingly, spermidine-secreting S. boulardii strains were significantly more effective than wild-type S. boulardii in reducing colitis symptoms as well as colitis-associated carcinogenesis in mice. These results suggest that in situ spermidine secretion by engineered synthetic biotic yeast strains may be an effective and low-cost therapy to mitigate inflammatory bowel disease and associated colon cancer.